Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin

NCT01576328 is registered in ClinicalTrials.gov with Mesoblast, Ltd. as lead sponsor.

NCT NCT01576328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01576328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin
Lead sponsor
Mesoblast, Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2012
Completion date
October 31, 2015
Enrollment
61 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes